-
Intertwin discordance in fetal size at 11-13 weeks' gestation and pregnancy outcome.
Litwinska E, Syngelaki A, Cimpoca B, Sapantzoglou I, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;55:189-197. pdf -
Diagnosis of major heart defects by routine first-trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus.
Minnella GP, Crupano FM, Syngelaki A, Zidere V, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;55:637-644. pdf -
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Intelligent Non-invasive Diagnosis of Aneuploidy: Raw Values and Highly Imbalanced Dataset.
Neocleous A, Nicolaides K, Schizas C.
IEEE J Biomed Health Inform 2017;21:1271-1279. pdf -
First Trimester Noninvasive Prenatal Diagnosis: A Computational Intelligence Approach.
Neocleous AC, Nicolaides KH, Schizas CN.
IEEE J Biomed Health Inform 2016;20:1427-38. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
Fetal right ventricular contraction and relaxation times at 11-13 weeks' gestation by speckle tracking imaging.
Persico N, Fabietti I, Baffero G, Fedele L, Nicolaides KH.
Ultrasound Obstet Gynecol 2014;43:284-90. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks' gestation.
Maiz N, Wright D, Ferreira AF, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012;31:221-9. -
Prevalence and Outcome of Absence of Ductus Venosus at 11 to 13(+6) Weeks.
Staboulidou I, Pereira S, Cruz JJ, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:35-40. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Ductus venosus flow at 11-13 weeks in the prediction of birth weight discordance in monochorionic twins.
Matias A, Maiz N, Montenegro N, Nicolaides K.
J Perinat Med 2011;39:467-70. -
Contribution of ductus venosus doppler in first-trimester screening for major cardiac defects.
Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH.
Fetal Diagn Ther 2011;29:127-34. -
Additional first-trimester ultrasound markers.
Sonek J, Nicolaides K.
Clin Lab Med 2010;30:573-92. -
Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications.
Maiz N, Nicolaides KH.
Fetal Diagn Ther 2010;28:65-71. -
Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:512-7.